Baidu
map

政策与人文

订阅

MedSci主页 / 所有栏目 / 政策与人文

通过一致性评价药品研发费用汇总

2019-10-24 佚名 医药魔方Info

一致性评价仿制药价格下降
关注

据医药魔方不完全统计，上市公司公告过研发费用的通过一致性评价药品（包含新4类视同通过）共有77个，其中66个低于1000万元，11个高于1000万元。

据医药魔方不完全统计，上市公司公告过研发费用的通过一致性评价药品（包含新4类视同通过）共有77个，其中66个低于1000万元，11个高于1000万元。



版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2045687, encodeId=1121204568efa, content=<a href='/topic/show?id=f9ec8e465b4' target=_blank style='color:#2F92EE;'>#药品研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87465, encryptionId=f9ec8e465b4, topicName=药品研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Sep 24 02:00:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906937, encodeId=836b190693e38, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Wed Nov 20 15:00:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300323, encodeId=a542130032359, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 26 07:00:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444590, encodeId=1b9f144459057, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Oct 26 07:00:00 CST 2019, time=2019-10-26, status=1, ipAttribution=)]
    2020-09-24 huanbaofeng

    #药品研发#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2045687, encodeId=1121204568efa, content=<a href='/topic/show?id=f9ec8e465b4' target=_blank style='color:#2F92EE;'>#药品研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87465, encryptionId=f9ec8e465b4, topicName=药品研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Sep 24 02:00:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906937, encodeId=836b190693e38, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Wed Nov 20 15:00:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300323, encodeId=a542130032359, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 26 07:00:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444590, encodeId=1b9f144459057, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Oct 26 07:00:00 CST 2019, time=2019-10-26, status=1, ipAttribution=)]
    2019-11-20 zhanfl

    #一致性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2045687, encodeId=1121204568efa, content=<a href='/topic/show?id=f9ec8e465b4' target=_blank style='color:#2F92EE;'>#药品研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87465, encryptionId=f9ec8e465b4, topicName=药品研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Sep 24 02:00:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906937, encodeId=836b190693e38, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Wed Nov 20 15:00:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300323, encodeId=a542130032359, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 26 07:00:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444590, encodeId=1b9f144459057, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Oct 26 07:00:00 CST 2019, time=2019-10-26, status=1, ipAttribution=)]
    2019-10-26 lqvr

    #研发#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2045687, encodeId=1121204568efa, content=<a href='/topic/show?id=f9ec8e465b4' target=_blank style='color:#2F92EE;'>#药品研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87465, encryptionId=f9ec8e465b4, topicName=药品研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Sep 24 02:00:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906937, encodeId=836b190693e38, content=<a href='/topic/show?id=d91e1943441' target=_blank style='color:#2F92EE;'>#一致性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19434, encryptionId=d91e1943441, topicName=一致性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Wed Nov 20 15:00:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300323, encodeId=a542130032359, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Oct 26 07:00:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444590, encodeId=1b9f144459057, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Oct 26 07:00:00 CST 2019, time=2019-10-26, status=1, ipAttribution=)]
    2019-10-26 huagfeg

    #评价#

    0

相关资讯

化学药品注射剂仿制药一致性评价技术要求征求意见

10月15日，国家药监局就《化学药品注射剂仿制药质量和疗效一致性评价技术要求（征求意见稿）》（以下简称《技术要求》）、《已上市化学药品注射剂仿制药质量和疗效一致性评价申报资料要求（征求意见稿）》（以下简称《申报要求》）公开征求意见。《技术要求》对参比制剂、处方工艺技术、原辅包质量控制技术、质量研究与控制技术、稳定性研究技术、特殊注射剂一致性评价、改规格注射剂、药品说明书、药品标准、无需开展一致性评

干货：注射剂一致性评价九问九答

注射剂一致性评价九问九答

仿制药一致性评价受理号达1289个 通过308个

截止2019年7月18日，CDE承办的一致性评价受理号已达1289个，共计373个品种，涉及383家药企；其中，289目录品种受理号611个，共计133个品种。注射剂受理号349个，共计107个品种。

2019年国内临床试验年中报告，一致性评价BE试验占19%

随着仿制药质量和疗效一致性评价等政策的出台，临床试验的关注度不断提高。1.药物类别2019年上半年，CDE药物临床试验登记平台总共公示961个临床试验。其中，化学药物745个，生物制品186个，中药/天然药物30个。2.国内试验和国际多中心试验目前药物临床试验平台中的临床试验多以国内试验为主，2019年上半年总计47个国际多中心试验，大多都是3期试验，主要研究安全性和有效性。从药品来看，基本均为新

价格杀来了！ 41品种因未过一致性评价遭强制降价

2019年7月12日，江西省医药采购服务中心一则《关于公示调整未通过仿制药质量和疗效一致性评价药品采购价格的通知》，将这一趋势交待的清清楚楚。《通知》称，经江西省医疗保障局同意，拟将一批未通过仿制药质量与疗效一致性评价药品的采购价，调整至该品规通过品种的最低价。

国家卫健委：建立耗材一致性评价机构

带量采购的基石，耗材一致性评价，要来了。 建立耗材一致性评价机构 8月12日，国家医保局发布《国家医疗保障局对十三届全国人大二次会议第6395号建议的答复》（下称“《答复》”）称：下一步，国家卫生健康委将配合相关管理部门建立耗材一致性评价机构。

Baidu
map
Baidu
map
Baidu
map